Skip to main content
SpringerLink
Log in

Psychopharmaka

  • Chapter
Arzneiverordnungs-Report 2005

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 34.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Anonym (2003): Lithium-Therapie bei der manisch-depressiven Erkrankung: Immer noch der Standard? Arzneimittelbrief 37: 49–51.

    Google Scholar 

  • Apter JT, Allen LA (1999): Buspirone: future directions. J Clin Psychopharmacol 19: 86–93.

    Article  CAS  PubMed  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (1997): Empfehlungen zur Therapie der Depression. 1. Aufl. Sonderheft Arzneiverordnung in der Praxis. September 1997. 2.Aufl., im Druck (2005).

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (2003): Empfehlungen zur Therapie von Angst-und Zwangsstörungen. 2. Aufl. Sonderheft Arzneiverordnung in der Praxis.

    Google Scholar 

  • Baptista T, Lacruz A, Angeles F, Silvera R, de Mendoza S, Mendoza MT et al (2001): Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry 34: 223–231.

    CAS  PubMed  Google Scholar 

  • Barbenel DM, Yusufi B, O’shea D, Bench CJ (2000): Mania in a patient receiving testosterone replacement postorchidectomy taking St John’s wort and sertraline. J Psychopharmacol 14: 84–86.

    CAS  PubMed  Google Scholar 

  • Barbui C, Hotopf M (2001): Amitriptyline vs. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Brit J Psychiatry 178: 129–144.

    CAS  Google Scholar 

  • Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP et al (2000): Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev 2000 (4): CD002791.

    Google Scholar 

  • Bauer M, Dopfner S (1999): Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 19: 427–434.

    CAS  PubMed  Google Scholar 

  • Bauer M, Whybrow PC, Angst C, Verslani M, Möller H-J (2002):World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3: 5–43.

    PubMed  Google Scholar 

  • Baumann P (1996): Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31: 444–469.

    CAS  PubMed  Google Scholar 

  • Baumann P, Zullino DF, Eap CB (2002): Enantiomers’ potential in psychopharmacology — a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol 12: 433–444.

    Article  CAS  PubMed  Google Scholar 

  • Benkert O, Szegedi A, Kohnen R (2000): Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 61: 656–663.

    CAS  PubMed  Google Scholar 

  • Bielski RJ, Ventura D, Chang CC (2004): A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 65: 1190–1196.

    CAS  PubMed  Google Scholar 

  • Birmes P, Coppin D, Schmitt L, Lauque D (2003): Serotonin syndrome: a brief review. CMAJ 168: 1439–1442.

    PubMed  Google Scholar 

  • Bjerkenstedt L, Edman GV, Alken RG, Mannel M (2005): Hypericum extract LI 160 and fluoxetine in mild to moderate depression. A randomised, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci 255: 40–47.

    Article  PubMed  Google Scholar 

  • Bonnet U (2003):Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 9: 97–140.

    CAS  PubMed  Google Scholar 

  • Braun M, Strasser RH (1997): Trizyklische Antidepressiva und kongestive Kardiomypathie. Internist 38: 1236–1238.

    CAS  PubMed  Google Scholar 

  • Caley CF, Weber SS (1995): Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Ann Pharmacother 29: 152–160.

    CAS  PubMed  Google Scholar 

  • Carriere P, Bonhomme D, Lemperiere T (2000): Amisulpride has a superior benefit/ risk profile to haloperidol in schizophrenia: results of a multicentre, doubleblind study (the Amisulpride Study Group). Eur Psychiatry 15: 321–329.

    CAS  PubMed  Google Scholar 

  • Carter CS, Mulsant BH, Sweet RA, Maxwell RA, Coley K et al (1995): Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. Psychopharmacol Bull 31: 719–25.

    CAS  PubMed  Google Scholar 

  • Chick J, Howlett H, Morgan MY, Ritson B (2000): United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35: 176–187.

    CAS  PubMed  Google Scholar 

  • Chouinard G, Jones B, Remington G, Bloom D, Addington D et al (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25–40.

    CAS  PubMed  Google Scholar 

  • Chuang DM (2004): Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases ? Crit Rev Neurobiol 16: 83–89.

    Article  CAS  PubMed  Google Scholar 

  • Colonna L, Saleem P, Dondey-Nouvel L, Rein W (2000): Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 15: 13–22.

    CAS  PubMed  Google Scholar 

  • Correll CU, Leucht S, Kane JM (2004): Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161: 414–425.

    Article  PubMed  Google Scholar 

  • Csernansky JG, Mahmoud R, Brenner R (2002): A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346: 16–22.

    Article  CAS  PubMed  Google Scholar 

  • Davis JM, Chen N, Glick ID (2003): A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553–564.

    CAS  PubMed  Google Scholar 

  • De Abajo FJ, Rodriguez LAG, Montero D (1999): Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. Brit Med J 319: 1106–1109.

    PubMed  Google Scholar 

  • De Smet PAGM, Touw DJ (2000): Safety of St John’s wort (Hypericum perforatum). Lancet 355: 575–576.

    PubMed  Google Scholar 

  • Dettling M, Hellweg R, Cascorbi I, Deichle U, Weise L, Müller-Oerlinghausen B (1999): Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine? Pharmacopsychiatry 32: 110–112.

    CAS  PubMed  Google Scholar 

  • Di Carlo G, Borreli F, Ernst E, Izzo AA (2001): St John’s wort: Prozac from the plant kingdom. Trends Pharmacol Sci 22: 292–297.

    PubMed  Google Scholar 

  • Dinan TG (2002): Lithium in bipolar mood disorder. Evidence suggests that lithium should still be first choice for prophylactic treatment. Brit Med J 324: 988–989.

    Google Scholar 

  • Donovan S, Clayton A, Beeharry M, Jones S, Kirk C, Waters K et al (2000): Deliberate self-harm and antidepressant drugs. Investigation of a possible link. Br J Psychiatry 177: 551–556.

    Article  CAS  PubMed  Google Scholar 

  • Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S (2000): Olanzapine for schizophrenia. Cochrane Database Syst Rev 2: CD001359.

    PubMed  Google Scholar 

  • Einarson TR, Arikian SR, Casciano J, Doyle JJ (1999): Comparison of extendedrelease venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 21: 296–308.

    Article  CAS  PubMed  Google Scholar 

  • Elliger T, Englert E, Freisleder FJ, Friedrich M, Gierow B et al (1994): Zur Behandlung schizophrener Psychosen des Kindes-und Jugendalters mit Clozapin (Leponex). Konsensuskonferenz vom 4. März 1994, Kinder und Jugendpsychiatrie. Z Kinder-Jugendpsychiat 22: 325–327.

    Google Scholar 

  • Elliger TJ, Trott GE, Nissen G (1990): Prevalence of psychotropic medication in childhood and adolescence in the Federal Republic of Germany. Pharmacopsychiatry 23: 38–44.

    CAS  PubMed  Google Scholar 

  • Ener RA, Meglathery SB, van Decker WA, Gallagher RM (2003): Serotonin syndrome and other serotonergic disorders. Pain Medicine 4: 63–74.

    Article  PubMed  Google Scholar 

  • Ernst CL, Goldberg JF (2004): Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 12: 14–41.

    PubMed  Google Scholar 

  • Ferguson JM, Wesnes KA, Schwartz GE (2003): Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 18: 9–14.

    PubMed  Google Scholar 

  • Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B (2005): Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomized controlled trials. BMJ 330: 396–402.

    CAS  PubMed  Google Scholar 

  • Franchini L, Zanardi R, Gasperini M, Perez J, Smeraldi E (1996): Fluvoxamine and lithium in long-term treatment of unipolar subjects with high recurrence rate. J Affect Disord 38: 67–69.

    Article  CAS  PubMed  Google Scholar 

  • Frank E, Kupfer DJ, Perel JM (1990): Three-years outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47: 1093–1099.

    CAS  PubMed  Google Scholar 

  • Gale C, Oakley-Browne M (2000): Anxiety disorder. Brit Med J 321: 1204–1207.

    CAS  PubMed  Google Scholar 

  • Gastpar M, Singer A, Zeller K (2005): Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 38: 78–86.

    Article  CAS  PubMed  Google Scholar 

  • Geddes J, Freemantle N, Harrison P et al (2000): Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Brit Med J 321: 1371–1376.

    CAS  PubMed  Google Scholar 

  • Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2001): SSRIs versus other antidepressants for depressive disorder. Update Software Ltd Oxford, The Cochrane Library — Issue 1.

    Google Scholar 

  • Geiselmann B, Linden M (1991): Prescription and intake patterns in long-term and ultra-long-term benzodiazepine treatment in primary care practice. Pharmacopsychiatry 24: 55–61.

    CAS  PubMed  Google Scholar 

  • Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E (2000): Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 283: 3082–3088.

    Article  CAS  PubMed  Google Scholar 

  • Goodnick PJ, Barrios CA (2001): Use of olanzapine in non-psychotic psychiatric disorders. Expert Opin Pharmacother 2: 667–680.

    CAS  PubMed  Google Scholar 

  • Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003): Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290: 1467–1473.

    Article  CAS  PubMed  Google Scholar 

  • Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S et al (2004): A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65: 432–441.

    CAS  PubMed  Google Scholar 

  • Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A et al (1996): Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J Affect Disord 40: 179–190.

    Article  CAS  PubMed  Google Scholar 

  • Guelfi JD, Ansseau M, Timmerman L, Korsgaard S (2001): Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 21: 425–431.

    Article  CAS  PubMed  Google Scholar 

  • Gunnel D, Ashby D (2004): Antidepressants and sucide: what is the balance of benefit and harm. BMJ 329: 34–38.

    Google Scholar 

  • Guzelcan Y, Scholte WF, Assies J, Becker HE (2001): Mania during the use of a combination preparation with St. John’s wort (Hypericum perforatum). Ned Tijdschr Geneeskd 6: 1943–1945.

    Google Scholar 

  • Healy D (2003): Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72: 71–79.

    PubMed  Google Scholar 

  • Hirschfeld RM, Kasper S (2004): A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol. 7:507–522.

    Article  CAS  PubMed  Google Scholar 

  • Hypericum Depression Trial Study Group (2002): Effect of Hypericum perforatum (St John’s Wort) in major depressive disorder. JAMA 287: 1807–1814.

    Article  Google Scholar 

  • Jick H, Kaye JA, Jick SS (2004): Antidepressants and the risk of suicidal behaviors. JAMA 292: 338–343.

    CAS  PubMed  Google Scholar 

  • Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL (2004): Efficacy and safety of antidepressants for children and adolescents. BMJ 328: 879–883.

    Article  CAS  PubMed  Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H (1988): Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796.

    CAS  PubMed  Google Scholar 

  • Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K (2003): Longacting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125–1132.

    Article  PubMed  Google Scholar 

  • Kappler J, Menges C, Ferbert A, Ebel H (1994): Schwere „Spät“dystonie nach „ Neuroleptanxiolyse“ mit Fluspirilen. Nervenarzt 65: 66–68.

    CAS  PubMed  Google Scholar 

  • Kasper S (1996): Mirtazapin. Klinisches Profil eines noradrenalin-und serotoninspezifischen Antidepressivums. Arzneimitteltherapie 14(9): 257–259.

    Google Scholar 

  • Kimko HC, Cross JT, Abernethy DR (1999): Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmakokinet 37: 457–470.

    CAS  Google Scholar 

  • Knopf H, Melchert H-U (2003): Bundes-Gesundheitssurvey: Arzneimittelgebrauch. Robert-Koch-Institut Berlin (Hrsg).

    Google Scholar 

  • Knuppel L, Linde K (2004): Adverse effects of St. John’s Wort: a systematic review. J Clin Psychiatry 65: 1470–1479.

    PubMed  Google Scholar 

  • Kornhuber J (1994): Potentielle Antipsychotica mit neuartigen Wirkmechanismen. In: Riederer P, Laux G, Pöldinger W (Hrsg): Neuropsychopharmaka, Bd. 4: Neuroleptica. Springer-Verlag, Wien New York, S. 185–196.

    Google Scholar 

  • Lapierre YD (1989): A review of trimipramine 30 years of clinical use. Drugs 38(suppl 1): 17–24.

    PubMed  Google Scholar 

  • Laties AM (2002): Quetiapine and cataracts. Am J Psychiatry 159: 322–323.

    Article  PubMed  Google Scholar 

  • Laux G, Volz H-P, Möller H-J (1995): Newer and older monoamine oxidase inhibitors. CNS Drugs 3: 145–158.

    CAS  Google Scholar 

  • Lantz MS, Buchalter E, Giambanco V (1999): St. John’s wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 12: 7–10.

    CAS  PubMed  Google Scholar 

  • Lepine JP, Gastpar M, Mendlewicz J, Tylee A (1997): Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12: 19–29.

    CAS  PubMed  Google Scholar 

  • Lesch OM, Riegler A, Gutierrez K, Hertling I, Ramskogler K, Semler B et al (2001): The European acamprosate trials. Conclusions for research and therapy. J Biomed Sci 8: 89–95.

    CAS  PubMed  Google Scholar 

  • Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM (2003a): Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160: 1209–1222.

    Article  PubMed  Google Scholar 

  • Leucht S, Wahlbeck K, Hamann J, Kissling W (2003b): New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361: 1581–1589.

    Article  CAS  PubMed  Google Scholar 

  • Licino J, Wong M-L (2005): Depression, antidpressants and sucidality: a critical appraisal. Nature Rev. Drug Disc. 4, 165–171.

    Google Scholar 

  • Linde K, Berner M, Egger M, Mulrow C (2005): St John’s wort for depression: metaanalysis of randomised controlled trials. Br J Psychiatry 186: 99–107.

    Article  PubMed  Google Scholar 

  • Linden M, Gothe H (1993): Benzodiazepine substitution in medical practice.Analysis of pharmacoepidemiological data based on expert interviews. Pharmacopsychiatry 26: 107–113.

    CAS  PubMed  Google Scholar 

  • MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F et al (2003): Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. Brit Med J 326: 1014–1019.

    CAS  PubMed  Google Scholar 

  • Macritchie KAN, Geddes MR, Scott J, Haslam DRS, Goodwin GM (2001): Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorders. Cochrane Review. In: The Cochrane Library Issue 3. Oxford, Updated Software.

    Google Scholar 

  • March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J; Treatment for Adolescents With Depression Study (TADS) Team (2004): Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 292: 807–820.

    Google Scholar 

  • Marder SR, Meibach RC (1994): Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825–835.

    CAS  PubMed  Google Scholar 

  • Melkersson K, Dahl ML (2004): Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64: 701–723.

    CAS  PubMed  Google Scholar 

  • Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G (2004): Interaction of St John’s wort with conventional drugs: systematic review of clinical trials. BMJ 329: 27–30.

    Article  PubMed  Google Scholar 

  • Möller H-J (1999): Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4): 99–107.

    PubMed  Google Scholar 

  • Möller H-J, Volz HP, Reimann IW, Stoll KD (2001): Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 21: 59–65.

    PubMed  Google Scholar 

  • Moncrieff J (2001): Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nerv Ment Dis 189: 288–295.

    CAS  PubMed  Google Scholar 

  • Montgomery SA, Roberts A, Patel AG (1994): Placebo-controlled efficacy of antidepressants in continuation treatment. Int Clin Psychopharmacology 9: 49–53.

    Google Scholar 

  • Montgomery S, Ferguson JM, Schwartz GE (2003): The antidepressant efficacy of reboxetine in patients with severe depression. J Clin Psychopharmacol 23: 45–50.

    Article  CAS  PubMed  Google Scholar 

  • Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM et al. (2000): St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97: 7500–7502.

    CAS  PubMed  Google Scholar 

  • Moses EL, Mallinger AG (2000): St. John’s wort: three cases of possible mania induction. J Clin Psychopharmacol 20: 115–117.

    Article  CAS  PubMed  Google Scholar 

  • MTA Cooperative Group (1999): A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiat 56: 1073–1086.

    Google Scholar 

  • Müller-Oerlinghausen B (2001): Abhängigkeit und Mißbrauch von Substanzen. Dtsch ä rztebl 98: A1625–A1627.

    Google Scholar 

  • Müller-Oerlinghausen B, Berghöfer A (1999): Antidepressants and suicidal risk. J Clin Psychiatry 60(suppl 2): S94–S99.

    Google Scholar 

  • Müller-Oerlinghausen B, Berghöfer A, Bauer M (2002): Bipolar disorder. Lancet 359: 241–247.

    PubMed  Google Scholar 

  • Müller-Oerlinghausen B, Berghöfer A, Ahrens B (2003): The antisuicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry. Can J Psychiatry 48: 433–439.

    PubMed  Google Scholar 

  • Nierenberg AA, Burt T, Matthews J, Weiss AP (1999):Mania associated with St. John’s wort. Biol Psychiatry 46: 1707–1708.

    Article  CAS  PubMed  Google Scholar 

  • Oeljeschläger B, Müller-Oerlinghausen B (2004):Wege zur Optimierung der individuellen antidepressiven Therapie. Deutsches ärzteblatt 101: A 1337–1340.

    Google Scholar 

  • Olfson M, Marcus SC, Pincus HA, Zito JM, Thompson JW, Zarin DA (1998): Antidepressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry 55: 310–316.

    CAS  PubMed  Google Scholar 

  • Parker V, Wong AH, Boon HS, Seeman MV (2001): Adverse reactions to St John’s wort. Can J Psychiatry 46: 77–79.

    CAS  PubMed  Google Scholar 

  • Philipp M, Kohnen R, Hiller KO (1999): Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. Brit Med J 319: 1534–1538.

    CAS  PubMed  Google Scholar 

  • Rickels K, Rynn M (2002): Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 63(Suppl 14): 9–16.

    CAS  PubMed  Google Scholar 

  • Riederer P, Laux G, Pöldinger W (Hrsg) (1993): Neuropsychopharmaka Bd. 3 Antidepressiva und Phasenprophylaktika. Springer-Verlag, Wien New York.

    Google Scholar 

  • Rüther E, Degner D, Munzel U, Brunner E, Lenhard G, Biehl J, Vogtle-Junkert U (1999): Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry 32: 127–135.

    PubMed  Google Scholar 

  • Rush AJ et al. STAR*D Investigators Group (2004): Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:119–142.

    PubMed  Google Scholar 

  • Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, Calabrese J, Kupfer D, Rosenbaum JF (2003): Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 53: 1028–1042.

    Article  PubMed  Google Scholar 

  • Safer DJ (2000): Are stimulants overprescribed for youths with ADHD? Ann Clin Psychiatry 12: 55–62.

    Article  CAS  PubMed  Google Scholar 

  • Sass H, Soyka M, Mann K, Zieglgansberger W (1996): Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53: 673–680.

    CAS  PubMed  Google Scholar 

  • ’schizophrenia and Diabetes 2003’ Expert Consensus Meeting, Dublin, 3–4 October 2003: consensus summary. Br J Psychiatry 184(suppl 47): s112–s114.

    Google Scholar 

  • Schnyder U, Koller-Leiser A (1996): A double-blind, multicentre study of paroxetine and maprotiline in major depression. Can J Psychiatry 41: 239–244.

    CAS  PubMed  Google Scholar 

  • Schöpf J, Müller-Oerlinghausen B (2005): Standardpräparate der Psychopharmakotherapie. Lithium. 2.Aufl. Springer-Verlag, Berlin Heidelberg New York

    Google Scholar 

  • Schou M (1998): Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Pharmacopsychiatry 31: 210–215.

    CAS  PubMed  Google Scholar 

  • Schrader E (2000): Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 15: 61–68.

    CAS  PubMed  Google Scholar 

  • Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME et al (2001): Effectiveness of St John’s wort in major depression: a randomized controlled trial. JAMA 285: 1978–1986.

    Article  CAS  PubMed  Google Scholar 

  • Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002): Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180: 396–404.

    Article  PubMed  Google Scholar 

  • Snow V, Lascher S, Mottur-Pilson C, for the American College of Physicians — American Society of Internal Medicine (2000): Clinical guideline I. Pharmacological treatment of acute major depression and dysthymia. Ann Int Med 132: 739–742.

    Google Scholar 

  • Sramek JJ, Zarotsky V, Cutler NR (2002): Generalized anxiety disorder: treatment options. Drugs 62: 1635–1648.

    CAS  PubMed  Google Scholar 

  • Stip E (2000): Novel antipsychotics: issues and controversies. Typicality of pical neuroleptics. J Psychiatry Neurosci 25: 137–153.

    CAS  PubMed  Google Scholar 

  • Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, Gee MF, Simpson GM, Stevens MC, Lieberman JA. (2003): The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 29:15–31.

    PubMed  Google Scholar 

  • Swift RM (1999): Drug therapy for alcohol dependence. N Engl J Med 340: 1482–1490.

    Article  CAS  PubMed  Google Scholar 

  • Szegedi A, Kohnen R, Dienel A, Kieser M (2005): Acute treatment of erate to severe depression withhypericum extract WS 5570 (St John’s wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ 330: 503–507.

    Article  CAS  PubMed  Google Scholar 

  • Tandon R, Jibson MD (2003): Efficacy of newer generation antipsychotics in treatment of schizophrenia. Psychoneuroendocrinology 28: 9–26.

    CAS  PubMed  Google Scholar 

  • Taylor DM, McAskill R (2000): Atypical antipsychotics and weight gain — a systematic review. Acta Psychiatr Scand 101: 416–432.

    Article  CAS  PubMed  Google Scholar 

  • Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000): Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35: 202–209.

    CAS  PubMed  Google Scholar 

  • Thase ME (2003): Effectiveness of antidepressants: comparative remission es. J Clin Psychiatry 64(Suppl 2): 3–7.

    CAS  Google Scholar 

  • Thase ME, Entsuah R, Rudolph RL (2001a): Remission rates during atment with venlafaxine or selective reuptake inhibitors. Br J Psychiatry 178: 234–241.

    Article  CAS  PubMed  Google Scholar 

  • Thase ME, Nierenberg AA, Keller MB, Panagides J (2001b): Efficacy mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 62: 782–788.

    CAS  PubMed  Google Scholar 

  • Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA et al (2004): Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer v.mood stabilizer alone. Br J Psychiatry 184: 337–345.

    Article  PubMed  Google Scholar 

  • Trindade E, Menon D, Topfer LA, Coloma C (1998): Adverse effects ociated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a metaanalysis. Canad Med Ass J 159: 1245–1252.

    CAS  Google Scholar 

  • Van Walraven C, Mamdani MM, Wells PS, Williams JI (2001): Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. Brit Med J 323: 1–6.

    Google Scholar 

  • Volovka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP et al. (2004): Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 65: 57–61.

    Google Scholar 

  • Volz HP, Gleiter CH, Möller HJ (1996): Monoaminoxidasehemmer in Psychiatrie. Nervenarzt 67: 339–347.

    CAS  PubMed  Google Scholar 

  • Volz HP, Möller HJ, Reimann I, Stoll K (2000): Opipramol for the atment of somatoform disorders. Results from a placebo-controlled trial. Eur Neuropsychopharmacol 10: 211–217.

    Article  CAS  PubMed  Google Scholar 

  • Von Ferber L, Lehmkuhl G, Köster I, Döpfner M, Schubert I, ölich J, Ihle P (2003): Methylphenidatgebrauch in Deutschland. Dtsch ärztebl 100: C38–C43.

    Google Scholar 

  • Walsh BT, Seidman SN, Sysko R, Gould M (2002): Placebo response in dies of major depression.Variable, substantial and growing. JAMA 287: 1840–1847.

    Article  PubMed  Google Scholar 

  • Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD (2002): Effect of John’s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 71: 414–420.

    Article  CAS  PubMed  Google Scholar 

  • Wetterling T (2001): Bodyweight gain with atypical antipsychotics. A parative review. Drug Saf 24: 59–73.

    CAS  PubMed  Google Scholar 

  • Whittington CJ, Kendall T, Fonagy P, Cottrell D, Colgrove A, Boddington E 04): Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363: 1341–1345.

    Google Scholar 

  • Williams JW Jr, Mulrow CD, Chiquette E, Hitchcock Noël P, Aguilar C, Cornell J (2000): Clinical guideline, part 2. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 132: 743–756.

    CAS  PubMed  Google Scholar 

  • Woelk H (2000): Comparison of St John’s wort and imipramine for treating ression: randomised controlled trial. Brit Med J 321: 536–539.

    CAS  PubMed  Google Scholar 

  • Woods JH, Winger G (1995): Current benzodiazepine issues. Psychopharmacology 118: 107–115.

    CAS  PubMed  Google Scholar 

  • Zanoli P (2004): Role of hyperforin in the pharmacological activities of St. n’s Wort. CNS Drug Rev 10: 203–18.

    CAS  PubMed  Google Scholar 

  • Zhou S, Chan E, Pan SQ, Huang M, Lee EJ (2004): Pharmacokinetic eractions of drugs with St John’s wort. J Psychopharmacol 18: 262–76.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie und Toxikologie der Universität Würzburg, Versbacher Straße 9, 97078, Würzburg

    Prof. Dr. med. Martin J. Lohse

  2. Uferstraße 1, 69168, Wiesloch

    Privatdozentin Dr. med. Anna Lorenzen

  3. Jebenstraße 3, 10623, Berlin

    Prof. Dr. med. Bruno Müller-Oerlinghausen

Authors
  1. Prof. Dr. med. Martin J. Lohse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Privatdozentin Dr. med. Anna Lorenzen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. Bruno Müller-Oerlinghausen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Lohse, M.J., Lorenzen, A., Müller-Oerlinghausen, B. (2006). Psychopharmaka. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2005. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-30505-X_43

Download citation

  • DOI: https://doi.org/10.1007/3-540-30505-X_43

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28368-3

  • Online ISBN: 978-3-540-30505-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation